研報掘金丨東吳證券:首予天士力“買入”評級,華潤入主強強聯合
東吳證券研報指出,天士力為中藥現代化領軍企業,華潤入主,強強聯合,優勢互補。華潤三九和天士力有望實現中藥產業鏈的補鏈強鏈延鏈,發揮研發協同價值,提升創新發展能力,形成品牌勢能。一方面,天士力有望發揮中藥創新研發、智能化生產的優勢;另一方面,華潤三九強大的品牌打造能力和渠道優勢有望為天士力賦能,推動天士力產品院外市場的開拓,後續融合發展值得期待。公司基本盤穩中向好,研發能力靠前,華潤三九入主後有望發揮雙方優勢,進一步提質增效。首次覆蓋,給予“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.